PLA2G12A

Summary

PLA2G12A (phospholipase A2 group XIIA, HGNC:18554) is a protein-coding gene on chromosome 4q25, encoding Group XIIA secretory phospholipase A2 (Q9BZM1). PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides.

Secreted phospholipase A2 (sPLA2) enzymes liberate arachidonic acid from phospholipids for production of eicosanoids and exert a variety of physiologic and pathologic effects. Group XII sPLA2s, such as PLA2G12A, have relatively low specific activity and are structurally and functionally distinct from other sPLA2s (Gelb et al., 2000 [PubMed 11031251]).

Source: NCBI Gene 81579 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 46 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_030821

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18554
Approved symbol	PLA2G12A
Name	phospholipase A2 group XIIA
Location	4q25
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000123739
Ensembl biotype	protein_coding
OMIM	611652
Entrez	81579

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000243501, ENST00000502283, ENST00000502772, ENST00000507961, ENST00000858473, ENST00000858474

RefSeq mRNA: 1 — MANE Select: NM_030821 NM_030821

CCDS: CCDS3686

Canonical transcript exons

ENST00000243501 — 4 exons

Exon	Start	End
ENSE00000841706	109709989	109714495
ENSE00000841708	109718683	109718759
ENSE00000841709	109729602	109730070
ENSE00003588438	109717548	109717713

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 98.01.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.9696 / max 95.6140, expressed in 1750 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
53603	11.1427	1745
53602	1.1351	474
53601	0.6918	337

Top tissues by expression

263 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	98.01	gold quality
upper arm skin	UBERON:0004263	96.79	gold quality
kidney epithelium	UBERON:0004819	96.78	gold quality
endothelial cell	CL:0000115	96.53	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.28	gold quality
left ventricle myocardium	UBERON:0006566	96.00	gold quality
inferior vagus X ganglion	UBERON:0005363	95.87	gold quality
renal medulla	UBERON:0000362	95.78	gold quality
pons	UBERON:0000988	95.56	gold quality
medulla oblongata	UBERON:0001896	95.29	gold quality
parietal pleura	UBERON:0002400	95.26	gold quality
subthalamic nucleus	UBERON:0001906	95.05	gold quality
tibialis anterior	UBERON:0001385	95.01	gold quality
pancreatic ductal cell	CL:0002079	94.98	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.74	gold quality
ileal mucosa	UBERON:0000331	94.69	gold quality
germinal epithelium of ovary	UBERON:0001304	94.65	gold quality
superior vestibular nucleus	UBERON:0007227	94.57	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.43	gold quality
deltoid	UBERON:0001476	94.32	gold quality
nipple	UBERON:0002030	94.31	gold quality
substantia nigra pars compacta	UBERON:0001965	94.22	gold quality
ventral tegmental area	UBERON:0002691	94.13	gold quality
trigeminal ganglion	UBERON:0001675	94.12	gold quality
visceral pleura	UBERON:0002401	94.10	gold quality
epithelial cell of pancreas	CL:0000083	94.09	gold quality
hindlimb stylopod muscle	UBERON:0004252	93.46	gold quality
dorsal root ganglion	UBERON:0000044	93.44	gold quality
cardia of stomach	UBERON:0001162	93.22	gold quality
corpus callosum	UBERON:0002336	93.07	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.82
E-GEOD-125970	yes	4.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

140 targeting PLA2G12A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358

Literature-anchored findings (GeneRIF, showing 4)

• cellular arachidonate (AA) release and prostaglandin (PG) production are regulated by novel classes of secretory phospholipase A(2)s (sPLA(2)s), groups III and XII (PMID:12522102)
• The study demonstrated that PLA2G12A SNPs or haplotypes might influence the susceptibility to schizophrenia in the Han Chinese population from Northeast China. (PMID:27434078)
• The results of this study revealed that PLA2G12A rs3087494 polymorphism did not influence age at onset in patients with schizophrenia. (PMID:29527719)
• PLA2G12A protects against diet-induced obesity and insulin resistance by enhancing energy expenditure and clearance of circulating triglycerides. (PMID:38703030)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	pla2g12a	ENSDARG00000070454
mus_musculus	Pla2g12a	ENSMUSG00000027999
rattus_norvegicus	Pla2g12a	ENSRNOG00000057470
drosophila_melanogaster	GXIVsPLA2	FBGN0036545
caenorhabditis_elegans		WBGENE00016288
caenorhabditis_elegans		WBGENE00018411

Paralogs (1): PLA2G12B (ENSG00000138308)

Protein

Protein identifiers

Group XIIA secretory phospholipase A2 — Q9BZM1 (reviewed: Q9BZM1)

Alternative names: Phosphatidylcholine 2-acylhydrolase 12A

All UniProt accessions (4): A0A0C4DGC6, D6RBP5, Q9BZM1, Q542Y6

UniProt curated annotations — full annotation on UniProt →

Function. PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Does not exhibit detectable activity toward sn-2-arachidonoyl- or linoleoyl-phosphatidylcholine or -phosphatidylethanolamine.

Subcellular location. Secreted. Cytoplasm.

Tissue specificity. Abundantly expressed in heart, skeletal muscle, kidney, liver and pancreas.

Cofactor. Binds 1 Ca(2+) ion per subunit.

Similarity. Belongs to the phospholipase A2 family.

RefSeq proteins (1): NP_110448* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010711	PLA2G12	Family
IPR033113	PLA2_histidine	Active_site
IPR036444	PLipase_A2_dom_sf	Homologous_superfamily

Pfam: PF06951

Catalyzed reactions (Rhea), 1 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) (RHEA:15801)

UniProt features (9 total): binding site 4, active site 2, signal peptide 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BZM1-F1	81.38	0.31

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 110; 125

Ligand- & substrate-binding residues (4): 88; 90; 92; 111

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-1482788	Acyl chain remodelling of PC
R-HSA-1482801	Acyl chain remodelling of PS
R-HSA-1482839	Acyl chain remodelling of PE
R-HSA-1482922	Acyl chain remodelling of PI
R-HSA-1482925	Acyl chain remodelling of PG
R-HSA-1483166	Synthesis of PA

MSigDB gene sets: 187 (showing top): WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, chr4q25, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, KEGG_MAPK_SIGNALING_PATHWAY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, TGACCTY_ERR1_Q2, KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY, GOBP_ORGANIC_ACID_TRANSPORT, UEDA_PERIFERAL_CLOCK, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_SECRETION, GOBP_LIPID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_TRANSPORT

GO Biological Process (4): phospholipid metabolic process (GO:0006644), lipid catabolic process (GO:0016042), arachidonate secretion (GO:0050482), lipid metabolic process (GO:0006629)

GO Molecular Function (6): A2-type glycerophospholipase activity (GO:0004623), calcium ion binding (GO:0005509), obsolete calcium-dependent phospholipase A2 activity (GO:0047498), protein binding (GO:0005515), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (2): extracellular region (GO:0005576), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	6

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lipid metabolic process	2
cellular anatomical structure	2
organophosphate metabolic process	1
catabolic process	1
icosanoid secretion	1
arachidonate transport	1
primary metabolic process	1
glycerophospholipase activity	1
carboxylic ester hydrolase activity	1
metal ion binding	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

678 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLA2G12A	PLA2G10	O15496	955
PLA2G12A	PLA2G3	Q9NZ20	929
PLA2G12A	PLA2G2D	Q9UNK4	898
PLA2G12A	PLA2G2A	P14555	875
PLA2G12A	PLA2G2E	Q9NZK7	623
PLA2G12A	PLA2G2C	Q5R387	616
PLA2G12A	PLA2G2F	Q9BZM2	612
PLA2G12A	PLA2G5	P39877	583
PLA2G12A	PLA2G4C	Q9UP65	570
PLA2G12A	PLA2G1B	P04054	542
PLA2G12A	ENPP2	Q13822	508
PLA2G12A	PLA2G4A	P47712	481
PLA2G12A	CYP2E1	P05181	471
PLA2G12A	PLA2G6	O60733	451
PLA2G12A	SMAD4	Q13485	429

IntAct

20 interactions, top by confidence:

A	B	Type	Score
GRN	PLA2G12A	psi-mi:“MI:0915”(physical association)	0.560
PLA2G12A	WFS1	psi-mi:“MI:0915”(physical association)	0.560
EPB41L3	AP3B1	psi-mi:“MI:0914”(association)	0.530
PLA2G12A	PXDN	psi-mi:“MI:0915”(physical association)	0.400
PLA2G12A	HSPA5	psi-mi:“MI:0915”(physical association)	0.400
PLA2G12A	WDTC1	psi-mi:“MI:0915”(physical association)	0.400
PLA2G12A	DVL2	psi-mi:“MI:0915”(physical association)	0.370
MEF2C	PLA2G12A	psi-mi:“MI:0915”(physical association)	0.370
PLA2G12A	RB1	psi-mi:“MI:0915”(physical association)	0.370
PLA2G12A	RPS6	psi-mi:“MI:0915”(physical association)	0.370
PLA2G12A	RPS15	psi-mi:“MI:0915”(physical association)	0.370
PLA2G12A	UMPS	psi-mi:“MI:0915”(physical association)	0.370
YWHAG	PLA2G12A	psi-mi:“MI:0915”(physical association)	0.370
PLA2G12A	UCK1	psi-mi:“MI:0915”(physical association)	0.370
TMEM37	PLA2G12A	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (16): PLA2G12A (Affinity Capture-MS), PXDN (Affinity Capture-MS), PLA2G12A (Affinity Capture-RNA), PLA2G12A (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), WDTC1 (Affinity Capture-MS), PLA2G12A (Synthetic Rescue), RPS6 (Two-hybrid), UCK1 (Two-hybrid), RB1 (Two-hybrid), UMPS (Two-hybrid), RPS15 (Two-hybrid), YWHAG (Two-hybrid), TMEM37 (Two-hybrid), PLA2G12A (Two-hybrid)

ESM2 similar proteins: A0A1L4BJ46, A0A5C1ZXT8, A0A5C2A2T2, A8WP66, F4JP36, H2KZU7, I7GQA7, O45879, O55159, O62301, O76411, P00630, P02675, P0C8L9, P0DKU2, P0DMI6, P0DPT7, P0DPT9, P0DPZ3, P0DPZ9, P0DXZ6, P0DY42, P14480, P16422, P42579, P58239, P59888, Q09553, Q10128, Q1WER1, Q3T0L5, Q5F381, Q6P9Z6, Q6PXP0, Q6T178, Q75QW1, Q8BGV3, Q8BJ83, Q8K0E8, Q8VCM7

Diamond homologs: Q99P27, Q9BX93, Q9BZM1, Q9EPR2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

46 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	38
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

695 predictions. Top by Δscore:

Variant	Effect	Δscore
4:109714341:T:TA	donor_gain	1.0000
4:109717542:CCTTA:C	donor_loss	1.0000
4:109717543:CTTA:C	donor_loss	1.0000
4:109717544:TTACC:T	donor_loss	1.0000
4:109717545:TA:T	donor_loss	1.0000
4:109717546:A:AT	donor_loss	1.0000
4:109717546:AC:A	donor_gain	1.0000
4:109717547:CC:C	donor_gain	1.0000
4:109717709:TTAAG:T	acceptor_gain	1.0000
4:109717710:TAAG:T	acceptor_gain	1.0000
4:109717714:C:CC	acceptor_gain	1.0000
4:109718681:A:AC	donor_gain	1.0000
4:109718682:C:CC	donor_gain	1.0000
4:109729617:A:AC	donor_gain	1.0000
4:109729618:C:CC	donor_gain	1.0000
4:109729631:T:TA	donor_gain	1.0000
4:109714492:CATG:C	acceptor_gain	0.9900
4:109717682:CACTT:C	acceptor_gain	0.9900
4:109717686:T:C	acceptor_gain	0.9900
4:109717690:C:CT	acceptor_gain	0.9900
4:109718661:T:C	donor_gain	0.9900
4:109718684:TGAAC:T	donor_gain	0.9900
4:109729597:CTCAC:C	donor_loss	0.9900
4:109729598:TCACC:T	donor_loss	0.9900
4:109729600:ACCG:A	donor_loss	0.9900
4:109729601:CCG:C	donor_gain	0.9900
4:109729636:G:A	donor_gain	0.9900
4:109714494:TG:T	acceptor_gain	0.9800
4:109714496:C:CC	acceptor_gain	0.9800
4:109717546:A:AC	donor_gain	0.9800

AlphaMissense

1230 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:109717636:C:A	K121N	0.998
4:109717636:C:G	K121N	0.998
4:109714436:A:C	Y171D	0.997
4:109717616:A:C	F128C	0.997
4:109717627:A:C	C124W	0.997
4:109717628:C:A	C124F	0.997
4:109717628:C:T	C124Y	0.997
4:109717679:C:G	C107S	0.997
4:109717679:C:T	C107Y	0.997
4:109717680:A:T	C107S	0.997
4:109718708:C:G	C87S	0.997
4:109718709:A:T	C87S	0.997
4:109729622:C:G	C63S	0.997
4:109729623:A:T	C63S	0.997
4:109714422:T:A	Q175H	0.996
4:109714422:T:G	Q175H	0.996
4:109714444:C:G	C168S	0.996
4:109714445:A:T	C168S	0.996
4:109717628:C:G	C124S	0.996
4:109717629:A:T	C124S	0.996
4:109717661:C:G	C113S	0.996
4:109717662:A:T	C113S	0.996
4:109717682:C:G	C106S	0.996
4:109717683:A:G	C106R	0.996
4:109717683:A:T	C106S	0.996
4:109718709:A:G	C87R	0.996
4:109714492:C:G	C152S	0.995
4:109714492:C:T	C152Y	0.995
4:109714493:A:T	C152S	0.995
4:109717592:C:G	C136S	0.995

dbSNP variants (sampled 300 via entrez): RS1000067548 (4:109711432 T>A,C), RS1000161169 (4:109718584 T>G), RS1000179770 (4:109712775 T>C), RS10004377 (4:109726968 G>A,C,T), RS1000548245 (4:109731721 AC>A), RS1000842685 (4:109725250 T>C,G), RS1001224666 (4:109729050 A>T), RS1001245827 (4:109709952 A>G), RS1001511511 (4:109724431 T>A,C), RS1001614234 (4:109716594 T>C), RS1001730303 (4:109716954 C>A,T), RS1001894260 (4:109722215 T>C), RS1001946508 (4:109716539 G>A,C), RS1001954142 (4:109714832 T>A,C), RS1002009933 (4:109724165 G>T)

Disease associations

OMIM: gene MIM:611652 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006611_118	HDL cholesterol	2.000000e-08
GCST006613_27	Triglycerides	1.000000e-12
GCST012232_11	Lipoprotein (a) levels	1.000000e-11
GCST90002397_19	Mean spheric corpuscular volume	4.000000e-11

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004530	triglyceride measurement
EFO:0006925	lipoprotein A measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4524005 (PROTEIN FAMILY), CHEMBL6122 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 272 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL148674	VARESPLADIB	2	272

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Phospholipase A₂

ChEMBL bioactivities

8 potent at pChembl≥5 of 9 total, top 8 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.25	IC50	56	nM	CHEMBL4593409
6.94	IC50	114	nM	VARESPLADIB
6.88	IC50	131	nM	VARESPLADIB
6.08	IC50	840	nM	CHEMBL5194852
6.04	IC50	910	nM	CHEMBL5200953
5.85	IC50	1410	nM	CHEMBL5179709
5.59	IC50	2580	nM	CHEMBL5207115
5.42	IC50	3810	nM	CHEMBL5203236

PubChem BioAssay actives

9 with measured affinity, of 43 total; 7 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2R)-3-[3-(5-benzyl-2-carbamoylphenyl)phenyl]-2-methylpropanoic acid	1631141: Inhibition of sPLA2 in human HepG2 cells	ic50	0.0140	uM
2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid	1614038: Inhibition of human recombinant sPLA2 assessed as reduction in 16:0 LPC formation after 30 mins by HPLC-MS analysis	ic50	0.1140	uM
3-[(2E)-2-[(3-methoxyphenyl)methylidene]hydrazinyl]-1H-quinoxalin-2-one	1859296: Inhibition of human PLA2G12A	ic50	0.8400	uM
1-(2,4-dihydroxyphenyl)-5H-pyrrolo[1,2-a]quinoxalin-4-one	1859296: Inhibition of human PLA2G12A	ic50	0.9100	uM
1-(3,4-dichlorophenyl)-5H-pyrrolo[1,2-a]quinoxalin-4-one	1859296: Inhibition of human PLA2G12A	ic50	1.4100	uM
1-(2,4-dinitrophenyl)-5H-pyrrolo[1,2-a]quinoxalin-4-one	1859296: Inhibition of human PLA2G12A	ic50	2.5800	uM
3-[(2E)-2-(thiophen-2-ylmethylidene)hydrazinyl]-1H-quinoxalin-2-one	1859296: Inhibition of human PLA2G12A	ic50	3.8100	uM

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	9
mono-(2-ethylhexyl)phthalate	increases methylation, decreases expression, increases abundance	2
entinostat	increases expression, affects cotreatment	2
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
trichostatin A	increases expression	1
cobaltous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	increases expression	1
Carbamazepine	affects expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Diclofenac	affects expression	1
Diethylhexyl Phthalate	increases abundance, increases methylation	1
Estradiol	increases expression	1
Hydrogen Peroxide	increases expression	1
Lead	affects expression	1
Methotrexate	increases expression	1
Selenium	affects cotreatment, decreases expression	1
Thiram	decreases expression	1
Tretinoin	increases expression	1
Vitamin E	affects cotreatment, decreases expression	1
Cyclosporine	increases expression	1
Antirheumatic Agents	increases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

17 unique, capped per target: 17 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4383327	Binding	Inhibition of human sPLA2	1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio. — Eur J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2B0	Abcam HeLa PLA2G12A KO	Cancer cell line	Female
CVCL_TE05	HAP1 PLA2G12A (-) 1	Cancer cell line	Male
CVCL_TE06	HAP1 PLA2G12A (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.